Table 2
Baseline Comparison of Intervention Groups
| SMT | Placebo | Enhanced Placebo | No Treatment Control | Total Sample | p- value for difference | |
|---|---|---|---|---|---|---|
| Sex (% female) | 21/28 (75.0) | 17/27 (63.0) | 20/27 (74.1) | 19/28 (68.0) | 77/110 (70.0) | 0.74 |
| Age | 32.07 (10.98) | 33.22 (13.29) | 31.56 (11.85) | 29.85 (12.09) | 31.68 (11.85) | 0.78 |
| Education (years) | 16.04 (2.33) | 15.59 (2.50) | 15.89 (2.38) | 16.57 (2.60) | 16.03 (2.45) | 0.51 |
| Duration of LBP (weeks) (median, interquartile range) | 12 (164.50) | 24 (100) | 36 (543) | 4 (108) | 16.03 (153) | 0.43 |
| ODI | 17.04 (9.17) | 14.22 (8.56) | 17.92 (13.31) | 20.04 (15.27) | 17.32 (11.95) | 0.35 |
| Usual Pain | 45.26 (26.21) | 43.78 (22.45) | 37.89 (22.13) | 33.93 (26.21) | 40.16 (23.33) | 0.24 |
| FABQ-PA | 12.78 (4.89) | 11.74 (3.05) | 12.41 (5.21) | 13.50 (5.68) | 12.61 (4.80) | 0.59 |
| FABQ-W | 10.92 (8.05) | 10.42 (7.44) | 9.23 (9.39) | 12.32 (8.07) | 10.75 (8.22) | 0.59 |
| TSK | 23.27 (6.25) | 22.46 (4.88) | 20.54 (5.04) | 22.42 (6.02) | 22.17 (5.59) | 0.35 |
| PCS | 16.08 (8.51) | 13.88 (9.66) | 14.88 (11.04) | 12.75 (11.67) | 14.37 (10.25) | 0.68 |